Navigation Links
WebMD Announces Third Quarter Financial Results
Date:11/3/2009

of the merger closing date of October 23, 2009, WebMD had approximately $1 billion in cash and investments and had outstanding approximately $515 million in aggregate principal amount of convertible notes.

Financial Guidance

The Company reaffirmed its financial guidance for the fourth quarter and calendar year 2009 today and narrowed the ranges for its anticipated revenue and Adjusted EBITDA by raising the low end of those ranges. This financial guidance reflects the prior financial guidance for the Company's former parent, HLTH Corporation, whose historical financial statements are required to be adopted by WebMD as a result of the merger.

For 2009, WebMD expects:

  • Total revenue to be approximately $430 million to $440 million, an increase of 15% to 18% over 2008;
  • Adjusted EBITDA to be approximately $106 million to $111 million, an increase of 24% to 25% over 2008;
  • Income from continuing operations to be approximately $11 million to $14 million, or $0.22 to $0.27 per share.

These amounts represent growth of approximately 19% to 23% in public portal advertising and sponsorship revenue and approximately 2% in private portal services revenue.

Additional detail is provided in a schedule attached to this release.

Analyst and Investor Conference Call

As previously announced, WebMD will hold a conference call with investors and analysts to discuss its third quarter results at 4:45 pm (eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information serv
'/>"/>

SOURCE WebMD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. FDA and WebMD Expand Consumer Health Information Partnership
2. WebMD to Present at the Canaccord Adams 29th Annual Global Growth Conference
3. WebMD Announces Second Quarter Financial Results
4. WebMD Launches Free Mobile Application For Physicians
5. HLTH and WebMD Announce Second Quarter Earnings Release Date and Conference Call
6. HLTH Corporation and WebMD Health Corp. Announce Agreement to Merge
7. WebMD to Present at Jefferies 3rd Annual Healthcare Conference
8. COPD Foundation announces launch of Lung Health Check on WebMD
9. HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call
10. WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK
11. WebMD to Present at the Morgan Stanley Technology Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...kin Care,s cult favorite Drying Lotion picked by E...2009 ELLE Beauty Award , ...e,s Drying Lotion has long been a cult favorite am...n care divas, but its selection by ELLE readers fo...ap into the mainstream limelight., , , , ,The ELL...
(Date:12/3/2009)...rning of diabetes, cardiovascular disease, researc... News) -- Pregnant women who develop gestational g... risk for metabolic syndrome three months after th...glucose intolerance is less severe than gestationa...of factors (including high blood pressure, obesity...
(Date:12/3/2009)...Treatment Clinics Also Remain Open , ...Centegra Health System is continuing to offer H1N1...tegra Primary Care (CPC) vaccination clinics sin...inics are at CPC sites in Huntley, Woodstock, Crys...,   From 4:30 to 7:30 p.m. Thursday, De...
(Date:12/3/2009)... whether they cause brain cancer, , , T...hones cause brain cancer has been a subject of ong...dence suggesting that they don,t. , A 30-year e...ndinavia found no substantial change in prevalence...rding to the report in the Dec. 3 online edition o...
(Date:12/3/2009)...e/ -- Chiltern International Limited (Chiltern), a...ding clinical development and staffing services in...e appointment of Dr. Sharon Moore as Executive V...s. Dr. Moore is based at Chiltern,s Bristol, Tenne...ith 15 years of industry experience. Prior to join...
Breaking Medicine News(10 mins):Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:No Increase in Brain Tumors Seen From Cell Phones 2Health News:No Increase in Brain Tumors Seen From Cell Phones 3Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2
...hy kidney from a cancer patient, in Scotland has r...s //. Scottish National Party MSP, Alex Neil has u... of the involved surgeon. He further intends... be taken against the offenders. 'We now need answ...
...dex as a tool and indicator of diet is being quest... foods. High-GI foods, like white bread and potato...and some studies have suggested that diets heavy i...ted blood sugar and diabetes have not been found b...
...ce to fill up the healthcare sector, which runs sh... recruitment not only fills // up the void but als...ove is based on the recommendations of a recent re...growing opportunities with India emerging as a maj...
...ed to antibiotics in the first year of their life ... Carlo Marra and other researchers at the Univers...n and 1,817 asthma cases found this, but suggested...ch case antibiotics are not useful, reported healt...
...nd under weather, when the weather is down- winter...gap between feeling low and depression, according ...affects nearly one in every ten people in the Unit...illness, and life at that time can seem absolutely...
...er, who is over the board regularly, its time to c...o kick the tendency. // Medical experts have issue...s, a disease of the liver is not far away, and is ...lly with those under the age of 45, since the year...
Other Medicine News:Health News:Bottleneck: High on Spirits Can Cause A Dispirited Liver, Leading To Cirrhosis! 2
(Date:12/3/2009)...c. 3 Cardium Therapeutic...ly-owned subsidiary, Tissue Repair Company, submit...e U.S. Food and Drug Administration (FDA) seeking ...t candidate based on positive data from the Compan...udy. Today,s submission with the FDA covers Excel...
(Date:12/3/2009)... Dec. 3 Apnex Medical, Inc., a pri... completed a second round of private equity financ...o complete a clinical study and develop a second g...y designed to treat obstructive sleep apnea (OSA)....n Associates, New Enterprise Associates (NEA), Pol...
(Date:12/3/2009)...f., Dec. 3 Jazz Pharmace...t Kathryn E. Falberg has been appointed Senior Vic...erg brings to Jazz Pharmaceuticals more than 20 ye... As Jazz Pharmaceutical,s CFO, Ms. Falberg will be...te finance, financial planning, investor relations...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Apnex Medical, Inc. Raises Additional $14 Million 2Apnex Medical, Inc. Raises Additional $14 Million 3Determining Insulin Pump Need for Diabetics 52889 1Determining Insulin Pump Need for Diabetics 52889 2Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 1Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 2Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 3Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 4Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 5Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 6Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 7Raptor Pharmaceuticals Corp and TorreyPines Therapeutics Inc Announce Merger Agreement 52887 8Employers See Well Designed Worksite Health and Wellness Programs as Strong Value in Down Economy 52884 1Employers See Well Designed Worksite Health and Wellness Programs as Strong Value in Down Economy 52884 2Employers See Well Designed Worksite Health and Wellness Programs as Strong Value in Down Economy 52884 3Employers See Well Designed Worksite Health and Wellness Programs as Strong Value in Down Economy 52884 4Employers See Well Designed Worksite Health and Wellness Programs as Strong Value in Down Economy 52884 5
...n To Affect 9-Fold More Longevity Genes Than Resve...t Alone - Independent Laboratory A...ers report that a,proprietary nutriceutical matrix...nes controlling energy metabolism, nine times broa...striction (mouse study --,Experimental Gerontology...
...se III Study Does Not Mean the End of Anti-Amyloid... studies,of potential new treatments for Alzheimer...l - increase the field,s knowledge and point scien..., according to research,reported today at the 2008...on Alzheimer,s Disease (ICAD 2008), in Chicago., ...
Other Medicine Technology:Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies 2Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 2Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 5Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 6Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 7Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 8Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 9Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 10Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 11
Lambert Sleeve Spreader
deJuan Micro Pic Forceps - Black
Kaplan Subretinal Forceps
Landers Vitrectomy Lens Forceps
Medicine Products: